Low-Cost Event-Driven TDF/FTC Prevents More HIV Infections Within Fixed Budgets Than Long-Acting CAB-LA, Study Finds

Infectious Disease Advisor (9/26, Kuhns) reports, “Low-cost event-driven tenofovir plus emtricitabine (TDF/FTC) prevents more HIV infections within fixed budgets than long-acting cabotegravir (CAB-LA), according to results of a study published in Clinical...